严重肥胖青少年2型糖尿病手术与药物治疗比较
该研究为Teen-LABS与TODAY数据的二次分析,比较严重肥胖合并2型糖尿病青少年接受减重手术或药物治疗的血糖控制等指标。结果显示手术组糖化血红蛋白下降、体重减轻,药物组糖化血红蛋白上升、体重增加,手术组部分需再次手术。
要点
- 手术组2年糖化血红蛋白从6.8%降至5.5%,药物组从6.4%升至7.8%。
- 手术组BMI下降29%,药物组BMI增加3.7%。
核心结论
- 与药物治疗相比,严重肥胖青少年2型糖尿病的手术治疗与更好的血糖控制、体重减轻及其他合并症改善相关。
研究设计与样本
- 研究为Teen-LABS与TODAY联盟数据的二次分析,Teen-LABS纳入242名≤19岁青少年,TODAY随机纳入699名10-17岁参与者。
- 分析比较了Teen-LABS中接受减重手术的30名严重肥胖合并2型糖尿病青少年与TODAY中接受药物治疗的63名同类青少年的数据。
主要发现
- Teen-LABS组2年内平均糖化血红蛋白从6.8%(95%CI 6.4%-7.3%)降至5.5%(95%CI 4.7%-6.3%)。
- TODAY组2年内平均糖化血红蛋白从6.4%(95%CI 6.1%-6.7%)升至7.8%(95%CI 7.2%-8.3%)。
- 与基线相比,Teen-LABS组BMI下降29%(95%CI 24%-34%),TODAY组BMI增加3.7%(95%CI 0.8%-6.7%)。
临床怎么用
- 对于严重肥胖合并2型糖尿病的青少年,手术治疗可能比标准药物治疗更有效改善血糖和体重,但需注意再次手术风险。
- 研究结果支持需要设计良好的前瞻性对照研究来明确手术在该人群中的作用,包括健康与手术结局。
局限性
- 本研究为二次分析,非随机对照,手术组与药物组来自不同队列,基线特征可能存在差异。
- 手术组样本量较小(30例),药物组63例,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Because of the substantial increase in the occurrence of type 2 diabetes in the pediatric population and the medical complications of this condition, therapies are urgently needed that will achieve better glycemic control than standard medical management. OBJECTIVE: To compare glycemic control in cohorts of severely obese adolescents with type 2 diabetes undergoing medical and surgical interventions. DESIGN, SETTING, AND PARTICIPANTS: A secondary analysis of data collected by the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) and Treatment Options of Type 2 Diabetes in Adolescents and Youth (TODAY) consortia was performed. Teen-LABS enrolled 242 adolescents (≤19 years of age) from March 1, 2007, through December 31, 2011. TODAY randomized 699 participants (aged 10-17 years) from July 24, 2004, through February 25, 2009. Data analysis was performed from July 6, 2015, to June 24, 2017. Anthropometric, clinical, and laboratory data from adolescents with severe obesity and type 2 diabetes who underwent treatment with metabolic or bariatric surgery in the Teen-LABS study or medical therapy in the TODAY study were compared. INTERVENTIONS: Teen-LABS participants underwent a primary bariatric surgical procedure; TODAY participants were randomized to receive metformin therapy alone or in combination with rosiglitazone or an intensive lifestyle intervention; insulin therapy was given in cases of progression of disease. MAIN OUTCOMES AND MEASURES: Glycemic control, body mass index, prevalence of elevated blood pressure, dyslipidemia, abnormal kidney function, and clinical adverse events were measured. RESULTS: Data from 30 participants from Teen-LABS (mean [SD] age at baseline, 16.9 [1.3] years; 21 [70%] female; 18 [66%] white) and 63 from TODAY (mean [SD] age at baseline, 15.3 [1.3] years; 28 [44%] female; 45 [71%] white) were analyzed. During 2 years, mean hemoglobin A1c concentration decreased from 6.8% (95% CI, 6.4%-7.3%) to 5.5% (95% CI, 4.7% -6.3%) in Teen-LABS and increased from 6.4% (95% CI, 6.1%-6.7%) to 7.8% (95% CI, 7.2%-8.3%) in TODAY. Compared with baseline, the body mass index decreased by 29% (95% CI, 24%-34%) in Teen-LABS and increased by 3.7% (95% CI, 0.8%-6.7%) in TODAY. Twenty-three percent of Teen-LABS participants required a subsequent operation during the 2-year follow-up. CONCLUSIONS AND RELEVANCE: Compared with medical therapy, surgical treatment of severely obese adolescents with type 2 diabetes was associated with better glycemic control, reduced weight, and improvement of other comorbidities. These data support the need for a well-designed, prospective controlled study to define the role of surgery for adolescents with type 2 diabetes, including health and surgical outcomes.
引用
- Inge TH, Laffel LM, Jenkins TM, et al. Comparison of Surgical and Medical Therapy for Type 2 Diabetes in Severely Obese Adolescents. JAMA Pediatr. 2018. PMID: 29532078. doi:10.1001/jamapediatrics.2017.5763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。